Evinacumab, sold under the brand name Evkeeza, is a
monoclonal antibody
A monoclonal antibody (mAb, more rarely called moAb) is an antibody produced from a cell Lineage made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell.
Monoclonal antibodies ...
medication
A medication (also called medicament, medicine, pharmaceutical drug, medicinal drug or simply drug) is a drug used to diagnose, cure, treat, or prevent disease. Drug therapy ( pharmacotherapy) is an important part of the medical field and ...
for the treatment of homozygous
familial hypercholesterolemia (HoFH).
Common side effects include nasopharyngitis (cold), influenza-like illness, dizziness, rhinorrhea (runny nose), and nausea. Serious hypersensitivity (allergic) reactions have occurred in the Evkeeza clinical trials.
Evinacumab binds to the angiopoietin-like protein 3 (
ANGPTL3
Angiopoietin-like 3, also known as ANGPTL3, is a protein that in humans is encoded by the ''ANGPTL3'' gene.
Function
The protein encoded by this gene is a member of the angiopoietin-like family of secreted factors. It is expressed predominantl ...
).
ANGPTL3 slows the function of certain enzymes that break down fats in the body.
Evinacumab blocks ANGPTL3, allowing faster break down of fats that lead to high cholesterol.
Evinacumab was approved for medical use in the United States in February 2021.
[ ]
History
Regeneron
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to i ...
invented evinacumab.
The effectiveness and safety of evinacumab were evaluated in a double-blind, randomized, placebo-controlled, 24-week trial enrolling 65 participants with homozygous familial hypercholesterolemia (HoFH).
In the trial, 43 participants received 15 mg/kg of evinacumab every four weeks and 22 participants received the placebo.
Participants were taking other lipid-lowering therapies as well.
The trial was conducted in the United States, Italy, France, Greece, Netherlands, Austria, Canada, Australia, New Zealand, Ukraine, South Africa, and Japan.
The primary measure of effectiveness was the percent change in
low-density lipoprotein
Low-density lipoprotein (LDL) is one of the five major groups of lipoprotein that transport all fat molecules around the body in extracellular water. These groups, from least dense to most dense, are chylomicrons (aka ULDL by the overall dens ...
(LDL-C) from the beginning of treatment to week 24.
At week 24, participants receiving evinacumab had an average 47% decrease in LDL-C while participants on the placebo had an average 2% increase.
The U.S.
Food and Drug Administration
The United States Food and Drug Administration (FDA or US FDA) is a List of United States federal agencies, federal agency of the United States Department of Health and Human Services, Department of Health and Human Services. The FDA is respon ...
(FDA) granted the application for evinacumab
orphan drug,
breakthrough therapy
Breakthrough therapy is a United States Food and Drug Administration designation that expedites drug development that was created by Congress under Section 902 of the 9 July 2012 Food and Drug Administration Safety and Innovation Act. The FDA's "br ...
, and
priority review
Priority review is a program of the United States Food and Drug Administration (FDA) to expedite the review process for drugs that are expected to have a particularly great impact on the treatment of a disease. The priority review voucher program ...
designations.
The FDA granted approval of Evkeeza to Regeneron Pharmaceuticals, Inc.
Society and culture
Legal status
On 22 April 2021, the
Committee for Medicinal Products for Human Use
The Committee for Medicinal Products for Human Use (CHMP), formerly known as Committee for Proprietary Medicinal Products (CPMP), is the European Medicines Agency's committee responsible for elaborating the agency's opinions on all issues regardin ...
(CHMP) of the
European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization under exceptional circumstances for the medicinal product Evkeeza, intended for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (HoFH).
The applicant for this medicinal product is Regeneron Ireland Designated Activity Company (DAC).
Evinacumab was approved for medical use in the European Union in June 2021.
References
Further reading
*
External links
*
Breakthrough therapy
Monoclonal antibodies
Orphan drugs
{{monoclonal-antibody-stub